{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:54:51Z","timestamp":1782320091277,"version":"3.54.5"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Patients with primary immunodeficiency (PIDs) depend on the presence of a variety of antibody specificities in intravenous immunoglobulin (IVIG). Using the tick-borne encephalitis virus (TBEV), geographic variability in IVIG antibody content was shown. Care should therefore be exercised when treating PIDs in a given geography, as only locally sourced plasma contains the antibody specificities against the circulating pathogens in the given locality.<\/jats:p>","DOI":"10.1128\/cvi.05705-11","type":"journal-article","created":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T05:39:35Z","timestamp":1330580375000},"page":"623-625","source":"Crossref","is-referenced-by-count":24,"title":["Tick-Borne Encephalitis Virus-Neutralizing Antibodies in Different Immunoglobulin Preparations"],"prefix":"10.1128","volume":"19","author":[{"given":"Philip O.","family":"Rabel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina B.","family":"Planitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Farcet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Kreil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2012,2,29]]},"reference":[{"key":"key20180919073603_B1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/506363","article-title":"Measles-virus-neutralizing antibodies in intravenous immunoglobulins","volume":"194","author":"Audet","year":"2006","journal-title":"J. Infect. Dis."},{"key":"key20180919073603_B2","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1086\/379335","article-title":"Intravenous immunoglobulin for infectious diseases: tailor-made or universal","volume":"188","author":"Bayry","year":"2003","journal-title":"J. Infect. Dis."},{"key":"key20180919073603_B3","first-page":"626","article-title":"Distribution of virus antibody activity among human IgG subclasses","volume":"43","author":"Beck","year":"1981","journal-title":"Clin. Exp. Immunol."},{"key":"key20180919073603_B4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2334-9-18","article-title":"Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection","volume":"9","author":"Ben-Nathan","year":"2009","journal-title":"BMC Infect. Dis."},{"key":"key20180919073603_B5","first-page":"335","article-title":"Tick-borne encephalitis among U.S. travelers to Europe and Asia\u20142000\u20132009","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"key20180919073603_B6","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1469-0691.2004.01022.x","article-title":"Tick-borne virus diseases of human interest in Europe","volume":"10","author":"Charrel","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"issue":"39","key":"key20180919073603_B7","article-title":"Tick-borne encephalitis in Europe, 2007 to 2009","volume":"16","author":"on behalf of the Working Group For Tick-Borne Encephalitis Virus.","year":"2011","journal-title":"Euro Surveill."},{"key":"key20180919073603_B8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jaci.2009.09.008","article-title":"Hepatitis A virus antibodies in immunoglobulin preparations","volume":"125","author":"Farcet","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"key20180919073603_B9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.vaccine.2011.12.013","article-title":"Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes","volume":"30","author":"Fritz","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073603_B10","unstructured":"GAO. 1998. Blood plasma safety\u2014plasma product risks are low if good manufacturing practices are followed\u2014report to the Chairman, Subcommittee on Human Resources, Committee on Government Reform and Oversight, House of Representatives. http:\/\/www.gao.gov\/assets\/230\/226266.pdf."},{"key":"key20180919073603_B11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0166-0934(89)90028-1","article-title":"Properties of IgG subclasses to human cytomegalovirus","volume":"25","author":"Gilljam","year":"1989","journal-title":"J. Virol. Methods"},{"key":"key20180919073603_B12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0166-3542(02)00206-1","article-title":"Tick-borne encephalitis","volume":"57","author":"Gritsun","year":"2003","journal-title":"Antiviral Res."},{"key":"key20180919073603_B13","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1016\/j.vaccine.2007.08.024","article-title":"Field effectiveness of vaccination against tick-borne encephalitis","volume":"25","author":"Heinz","year":"2007","journal-title":"Vaccine"},{"key":"key20180919073603_B14","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/JVI.02155-10","article-title":"Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile virus","volume":"85","author":"Hofmeister","year":"2011","journal-title":"J. Virol."},{"key":"key20180919073603_B15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0264-410X(92)90376-U","article-title":"Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes","volume":"10","author":"Holzmann","year":"1992","journal-title":"Vaccine"},{"key":"key20180919073603_B16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0264-410X(91)90315-W","article-title":"Humoral immunity against tick-borne encephalitis virus following manifest disease and active immunization","volume":"9","author":"Klockmann","year":"1991","journal-title":"Vaccine"},{"key":"key20180919073603_B17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0264-410X(97)00304-6","article-title":"Passive immunization reduces immunity that results from simultaneous active immunization against tick-borne encephalitis virus in a mouse model","volume":"16","author":"Kreil","year":"1998","journal-title":"Vaccine"},{"key":"key20180919073603_B18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jaci.2007.11.001","article-title":"Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations","volume":"121","author":"Lejtenyi","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"key20180919073603_B19","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.vaccine.2009.02.069","article-title":"Characterization of neutralizing antibodies to Far Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four tick-borne encephalitis vaccines in human","volume":"27","author":"Leonova","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073603_B20","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1099\/vir.0.011437-0","article-title":"Tick-borne encephalitis virus\u2014a review of an emerging zoonosis","volume":"90","author":"Mansfield","year":"2009","journal-title":"J. Gen. Virol."},{"key":"key20180919073603_B21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1423-0410.2002.00186.x","article-title":"A direct comparison of the antigen-specific antibody profiles of intravenous immunoglobulins derived from US and UK donor plasma","volume":"83","author":"Matejtschuk","year":"2002","journal-title":"Vox Sang."},{"key":"key20180919073603_B22","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"key20180919073603_B23","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/infdis\/jir122","article-title":"A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans","volume":"203","author":"Orlinger","year":"2011","journal-title":"J. Infect. Dis."},{"key":"key20180919073603_B24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jmv.21980","article-title":"Neutralization of different echovirus serotypes by individual lots of intravenous immunoglobulin","volume":"83","author":"Planitzer","year":"2011","journal-title":"J. Med. Virol."},{"key":"key20180919073603_B25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1086\/519392","article-title":"West Nile virus neutralization by US plasma-derived immunoglobulin products","volume":"196","author":"Planitzer","year":"2007","journal-title":"J. Infect. Dis."},{"key":"key20180919073603_B26","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3201\/eid1510.081668","article-title":"West Nile virus infection in plasma of blood and plasma donors, United States","volume":"15","author":"Planitzer","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"key20180919073603_B27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/TP.0b013e318224115e","article-title":"Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations","volume":"92","author":"Planitzer","year":"2011","journal-title":"Transplantation"},{"key":"key20180919073603_B28","unstructured":"ProMED-mail. 31 July 2009, posting date. Tick-borne encephalitis\u2014Russia (06): Chelyabinsk. Archive number 20090731.2691. http:\/\/www.promedmail.org\/direct.php?id=20090731.2691."},{"key":"key20180919073603_B29","unstructured":"ProMED-mail. 24 May 2009, posting date. Tick-borne encephalitis\u2014Russia (03): Yaroslavl. Archive number 20090524.1944. http:\/\/www.promedmail.org\/direct.php?id=20090524.1944."},{"key":"key20180919073603_B30","unstructured":"ProMED-mail. 21 July 2007, posting date. Tick-borne encephalitis\u2014Russia: Irkutsk, Arkhangelsk, Kemerovo. Archive number 20070721.2333. http:\/\/www.promedmail.org\/direct.php?id=20070721.2333."},{"issue":"10","key":"key20180919073603_B31","doi-asserted-by":"crossref","DOI":"10.2807\/ese.16.10.19812-en","article-title":"Increasing West Nile virus antibody titres in central European plasma donors from 2006 to 2010","volume":"16","author":"Rabel","year":"2011","journal-title":"Euro Surveill."},{"key":"key20180919073603_B32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.virol.2009.09.024","article-title":"Dengue virus neutralization is modulated by IgG antibody subclass and Fc\u03b3 receptor subtype","volume":"394","author":"Rodrigo","year":"2009","journal-title":"Virology"},{"key":"key20180919073603_B33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.tmaid.2010.06.004","article-title":"Tick-borne encephalitis: pathogenesis and clinical implications","volume":"8","author":"Ruzek","year":"2010","journal-title":"Travel Med. Infect. Dis."},{"key":"key20180919073603_B34","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.1016\/j.vaccine.2010.07.027","article-title":"Vaccination against tick-borne encephalitis virus tests specific IgG production ability in patients under immunoglobulin substitution therapy","volume":"28","author":"Seidel","year":"2010","journal-title":"Vaccine"},{"key":"key20180919073603_B35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ttbdis.2010.10.007","article-title":"Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia\u2014an overview","volume":"2","author":"Suess","year":"2011","journal-title":"Ticks Tick Borne Dis."},{"issue":"26","key":"key20180919073603_B36","article-title":"Tick-borne encephalitis in Europe and beyond\u2013the epidemiological situation as of 2007","volume":"13","author":"Suess","year":"2008","journal-title":"Euro Surveill."},{"key":"key20180919073603_B37","article-title":"Manufacturing of IVIG, p 13\u201342","volume-title":"Immunoglobulin therapy","author":"Teschner","year":"2010"},{"key":"key20180919073603_B38","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0264-410X(94)00032-I","article-title":"Vaccination against tick-borne encephalitis (TBE): influence of simultaneous application of TBE immunoglobulin on seroconversion and rate of adverse events","volume":"13","author":"von Hedenstrom","year":"1995","journal-title":"Vaccine"},{"key":"key20180919073603_B39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.tmaid.2010.05.007","article-title":"Tick borne encephalitis TBE\u2014vaccination in non-endemic countries","volume":"8","author":"Wiedermann","year":"2010","journal-title":"Travel Med. Infect. Dis."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.05705-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:46:51Z","timestamp":1627591611000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.05705-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,29]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,3,28]]},"published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1128\/CVI.05705-11"],"URL":"https:\/\/doi.org\/10.1128\/cvi.05705-11","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,29]]}}}